Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Colorectal Neoplasms 1

Interventions

enzalutamide 6radium Ra 223 dichloride 5Docetaxel 2Abiraterone Acetate 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1quemliclustat 1pembrolizumab 1atezolizumab 1apalutamide 1Standard of Care 1Radium-223 1Prednisone 1Nivolumab 1Ipilimumab 1Drug Therapy 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Prostatic Neoplasms, Castration-Resistant × quemliclustat × Clear all
NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡